Results 21 to 30 of about 329,623 (303)

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

Frontiers in Oncology, 2023
In a phase II trial of nivolumab in advanced thymic carcinoma (UMIN000022007), long SD (SD for more than 24 weeks) was seen in three patients and irAE (Gr2 or higher) was seen in four patients among 15 patients.
Yuki Katsuya, Yuki Katsuya, Shigehisa Kitano, Makiko Yamashita, Mayu Ouchi, Shigehiro Yagishita, Akinobu Hamada, Akinobu Hamada, Hiromi Nakamura, Fumie Hosoda, Tatsuhiro Shibata, Noriko Motoi, Noriko Motoi, Takayuki Nakayama, Takashi Seto, Shigeki Umemura, Yukio Hosomi, Miyako Satouchi, Makoto Nishio, Toshiyuki Kozuki, Toyoaki Hida, Toyoaki Hida, Yuichiro Ohe, Hidehito Horinouchi   +23 more
doaj   +1 more source

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella [PDF]

, 2017
Aiming to combine the flexibility of Brucella lumazine synthase (BLS) to adapt different protein domains in a decameric structure and the capacity of BLS and flagellin to enhance the immunogenicity of peptides that are linked to their structure, we ...
Berguer, Paula Mercedes, Biedma, Marina Elizabeth, Blancá, Bruno Martin, Cayet, D., Errea, Agustina Juliana, Goldbaum, Fernando Alberto, Hiriart, Yanina, Moreno, Griselda Noemí, Rinaldi, Jimena Julieta, Rossi, Andrés Hugo, Rumbo, Martín, Sirard, J.C.   +11 more
core   +3 more sources

Immunogenicity of CRISPR therapeutics—Critical considerations for clinical translation

Frontiers in Bioengineering and Biotechnology, 2023
CRISPR offers new hope for many patients and promises to transform the way we think of future therapies. Ensuring safety of CRISPR therapeutics is a top priority for clinical translation and specific recommendations have been recently released by the FDA.
Radwa Ewaisha, Radwa Ewaisha, Karen S. Anderson   +2 more
doaj   +1 more source

Clinical consequences of antibody formation, serum concentrations, and HLA-Cw6 status in psoriasis patients on Ustekinumab [PDF]

, 2019
Background: Ustekinumab for the treatment of psoriasis is currently administered in a standard dosing regimen. However, some patients tend to benefit from alternative dosing regimens, a step toward personalized medicine.
Busard, Celine, I, Costanzo, Antonio, De Keyser, Eline, Hutten, Barbara A., Lambert, Jo, Lanssens, Sven, Meuleman, Lieve, Spuls, Phyllis, I, van den Reek, Juul M., Zweegers, Jeffrey   +9 more
core   +1 more source

Predicting HLA CD4 Immunogenicity in Human Populations

Frontiers in Immunology, 2018
BackgroundPrediction of T cell immunogenicity is a topic of considerable interest, both in terms of basic understanding of the mechanisms of T cells responses and in terms of practical applications.
Sandeep Kumar Dhanda, Edita Karosiene, Lindy Edwards, Alba Grifoni, Sinu Paul, Massimo Andreatta, Daniela Weiskopf, John Sidney, Morten Nielsen, Morten Nielsen, Bjoern Peters, Bjoern Peters, Alessandro Sette, Alessandro Sette   +13 more
doaj   +1 more source

QuilA-adjuvanted T. gondii lysate antigens trigger robust antibody and IFNγ+ T cell responses in pigs leading to reduction in parasite DNA in tissues upon challenge infection [PDF]

, 2019
Toxoplasma gondii is an intracellular parasite of all mammals and birds, responsible for toxoplasmosis. In healthy individuals T. gondii infections mostly remain asymptomatic, however this parasite causes severe morbidity and mortality in ...
Cox, Eric, Devriendt, Bert, Dierick, Katelijne, Dorny, Pierre, Gisbert Algaba, Ignacio, Rahman, Mizanur, Verhaegen, Bavo   +6 more
core   +2 more sources

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development [PDF]

, 2017
Acknowledgments: The authors would like to acknowledge the funding support for this work from Scottish Enterprise [VNAR_001(2012)] and the Biotechnology and Biological Sciences Research Council (BB/K010905/1).Peer reviewedPublisher ...
Andrew J. Porter, Andrew J. Porter, Caroline Jane Barelle, Dawn Cornock, Gerard Donohoe, John Steven, Kenneth Saunders, Marina Kovaleva, Miguel F. Carvalho, Mischa R. Müller, Obinna C. Ubah, Thomas Baddeley   +11 more
core   +4 more sources

Human and bovine respiratory syncytial virus vaccine research and development [PDF]

, 2008
Human (HRSV) and bovine (BRSV) respiratory syncytial viruses (RSV) are two closely related viruses, which are the most important causative agents of respiratory tract infections of young children and calves, respectively.
Deplanche, Martine, Meyer, Gilles, Schelcher, François   +2 more
core   +2 more sources

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
A Olotu, Ali Mohammed, Amanda Leach, B Lell, David Schellenberg, E Macete, EV Macete, Francisca Machera, Grace Mwangoka, Hassan Mshinda, J Sacarlal, J Sacarlal, JJ Aponte, Joe Cohen, Johan Vekemans, KA Bojang, KE Kester, KP Asante, Marc Lievens, Marcel Tanner, Marie-Claude Dubois, MedDRA, MT White, Mwanajaa Shomari, Nahya Salim, Omar Juma, P Aide, P Aide, P Bejon, Richard Kamata, S Abdulla, S Owusu-Agyei, Salim Abdulla, ST Agnandji, ST Agnandji, ST Agnandji, Sulende Kubhoja, Terrell Carter, Thomas Aebi, Tonya Villafana, W Ripley Ballou, WHO, WHO, WHO/IVR   +43 more
core   +5 more sources

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications

Journal of Immunology Research, 2016
Today, potential immunogenicity can be better evaluated during the drug development process, and we have rational approaches to manage the clinical consequences of immunogenicity.
Anshu Kuriakose, Narendra Chirmule, Pradip Nair   +2 more
doaj   +1 more source